If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
=== Hydrolysis === The hydrolysis of nitriles RCN proceeds in the distinct steps under acid or base treatment to first give carboxamides RC(O)NH2 and then carboxylic acids RC(O)OH. The hydrolysis of nitriles to carboxylic acids is efficient. In acid or base, the balanced equations are as follows:
== General consequences == Point mutations that occur in non-coding sequences are most often without consequences, although there are exceptions. If the mutated base pair is in the promoter sequence of a gene, then the expression of the gene may change. Also, if the mutation occurs in the splicing site of an intron, then this may interfere with correct splicing of the transcribed pre-mRNA. By altering just one amino acid, the entire peptide may change, thereby changing the entire protein. The new protein is called a protein variant. If the original protein functions in cellular reproduction then this single point mutation can change the entire process of cellular reproduction for this organism. Point germline mutations can lead to beneficial as well as harmful traits or diseases. This leads to adaptations based on the environment where the organism lives. An advantageous mutation can create an advantage for that organism and lead to the trait's being passed down from generation to generation, improving and benefiting the entire population. The scientific theory of evolution is greatly dependent on point mutations in cells. The theory explains the diversity and history of living organisms on Earth. In relation to point mutations, it states that beneficial mutations allow the organism to thrive and reproduce, thereby passing its positively affected mutated genes on to the next generation. On the other hand, harmful mutations cause the organism to die or be less likely to reproduce in a phenomenon known as natural selection.
α (alpha)-cyclodextrin: 6 glucose subunits β (beta)-cyclodextrin: 7 glucose subunits γ (gamma)-cyclodextrin: 8 glucose subunits The largest well-characterized cyclodextrin contains 32 1,4-anhydroglucopyranoside units. Poorly-characterized mixtures, containing at least 150-membered cyclic oligosaccharides are also known.
Black neon tetras are egg-scattering free spawners, and they show no parental care for fry. The black and white stripes on their sides are used to keep the shoal in contact with each other in turbid water. As black neon tetras are so widely bred, they are no longer collected from the wild for trading. Present in both forest streams and seasonal floodwaters, the black neon tetra is an adaptable species. It prefers acidic habitats with running water and waterlogged debris as well as aquatic plants.
Sources: en.wikipedia.org
=== Iceland in 1986 === In 1986, at the age of 20, whilst at the University of Leeds, he crossed Iceland, together with three other students (Andrew Backhouse, David Brock and Shaun Fagan), from Seyðisfjörður in the east, through the interior to the north of the Vatnajökull ice fields, and then west to Reykjavík. The team encountered an 'ash storm', where storm force winds had whipped up fine black volcanic ash, and had to wear goggles and face masks to push on into the winds. In the rain shadow of the Vatnajökull, they ran out of water, then encountered a flash flood, as mud rushed down from the melting glaciers. They also had to survive on food contaminated with petrol that had leaked from their petrol stoves. This journey of 400 miles (640 km) raised £2,000 for the Royal Association for Disability and Rehabilitation. As part of the training for the walk across Iceland he ran the Leeds Marathon, in a time of 3 hours and 41 minutes. On the Icelandic trek, he came up with the idea of walking 6,000 miles (9,700 km), across Britain and America to raise money for Macmillan Cancer Support in Britain and hospice in America and Canada.
== Physical description == As in many chemical reactions, chemiluminescence starts with the combining of two compounds, say A and B, to give a product C. Unlike most chemical reactions, the product C converts to a further product, which is produced in an electronically excited state often indicated with an asterisk:
For services to People with Dementia and their Families. Dr. Emma Lucy Wilson. Director of Technical, Production and Costume, Royal Opera House. For services to the Performing Arts. William Wilson. Senior Officer, National Crime Agency. For services to Law Enforcement. Belinda Ann Winstone. Team Leader, Army Bereavement and Aftercare Services. For services to Military Families. Joan Harris Winterkorn. Archive and Manuscript Consultant and Member, Acceptance in Lieu Panel, Arts Council England. For services to Heritage and Culture. Theresa Wise. Chief Executive, Royal Television Society. For services to Broadcasting. Nicola Clare Wood. Senior Independent Director, Information Commissioner's Office. For services to Regulation. Mary Elizabeth Woods. Lately Nurse Consultant, The Royal Marsden NHS Foundation Trust. For services to Lymphoedema. Caroline Valerie Wright. Early Childhood Director, Bright Horizons Nursery. For services to Early Years Education. Judith Kathleen Wright. Trustee, Orders of St John Care Trust and lately Chair, St John Priory Group for Buckinghamshire. For voluntary service to the Order of St John. Stephen Richard Wright. Broadcaster. For services to Radio. Gloria Ingrid Wyse. Head of Research and Content, Business in the Community. For services to Diversity and Inclusion. Dr. Richard Kenneth Howard Wyse. Director of Clinical Development, Cure Parkinson's. For services to Medicine in Parkinson's Disease. Susan Yates. Officer, National Crime Agency. For services to Law Enforcement. Allan Reid Young. Head of Instrumental Music, Perth and Kinross.
Erin Shammel Baker is an American bioanalytical chemist specializing in developing ion mobility-mass spectrometry hybrid instruments for biological and environmental applications. Baker is an expert in the research of perfluoroalkyl and polyfluoroalkyl substances analysis.
Epidemiologists and public health officials use these models for several critical purposes: analyzing disease transmission dynamics, projecting the total number of infections and recoveries over time, estimating key epidemiological parameters such as the basic reproduction number (R0) or effective reproduction number (Rt), evaluating potential impacts of different public health interventions before implementation, and informing evidence-based policy decisions during disease outbreaks. Beyond infectious disease modeling, the approach has been adapted for applications in population ecology, pharmacokinetics, chemical kinetics, and other fields requiring the study of transitions between defined states. For such investigations and to consult decision makers, often more complex models are used.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.